187 related articles for article (PubMed ID: 25516504)
1. Role of osteopontin in osteosarcoma.
Li YS; Deng ZH; Zeng C; Lei GH
Med Oncol; 2015 Jan; 32(1):449. PubMed ID: 25516504
[TBL] [Abstract][Full Text] [Related]
2. The cancer-related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis.
Villanueva F; Araya H; Briceño P; Varela N; Stevenson A; Jerez S; Tempio F; Chnaiderman J; Perez C; Villarroel M; Concha E; Khani F; Thaler R; Salazar-Onfray F; Stein GS; van Wijnen AJ; Galindo M
J Cell Physiol; 2019 Aug; 234(8):13659-13679. PubMed ID: 30637720
[TBL] [Abstract][Full Text] [Related]
3. Expression of osteopontin and vascular endothelial growth factor in benign and malignant bone tumors.
Sulzbacher I; Birner P; Trieb K; Lang S; Chott A
Virchows Arch; 2002 Oct; 441(4):345-9. PubMed ID: 12404059
[TBL] [Abstract][Full Text] [Related]
4. High Expression of XRCC6 Promotes Human Osteosarcoma Cell Proliferation through the β-Catenin/Wnt Signaling Pathway and Is Associated with Poor Prognosis.
Zhu B; Cheng D; Li S; Zhou S; Yang Q
Int J Mol Sci; 2016 Jul; 17(7):. PubMed ID: 27455247
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin--an important downstream effector of S100A4-mediated invasion and metastasis.
Berge G; Pettersen S; Grotterød I; Bettum IJ; Boye K; Mælandsmo GM
Int J Cancer; 2011 Aug; 129(4):780-90. PubMed ID: 20957651
[TBL] [Abstract][Full Text] [Related]
6. MiR-374a promotes the proliferation of osteosarcoma cell proliferation by targeting Axin2.
Lu T; Zhang C; Chai MX; An YB; Jia JL
Int J Clin Exp Pathol; 2015; 8(9):10776-83. PubMed ID: 26617789
[TBL] [Abstract][Full Text] [Related]
7. Endocrine regulation and metabolic mechanisms of osteopontin in the development and progression of osteosarcoma, metastasis and prognosis.
Shao Z; Bi S
Front Endocrinol (Lausanne); 2022; 13():1100063. PubMed ID: 36714568
[TBL] [Abstract][Full Text] [Related]
8. CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells.
Li X; Xu R; Liu H; Fang K
Tumour Biol; 2016 Jun; 37(6):8139-44. PubMed ID: 26715273
[TBL] [Abstract][Full Text] [Related]
9. The cancer-related transcription factor Runx2 combined with osteopontin: a novel prognostic biomarker in resected osteosarcoma.
Liang S; Li Y; Wang B
Int J Clin Oncol; 2021 Dec; 26(12):2347-2354. PubMed ID: 34546483
[TBL] [Abstract][Full Text] [Related]
10. RUNX2 and Osteosarcoma.
Li N; Luo D; Hu X; Luo W; Lei G; Wang Q; Zhu T; Gu J; Lu Y; Zheng Q
Anticancer Agents Med Chem; 2015; 15(7):881-7. PubMed ID: 25738872
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of miR-664 is associated with enhanced osteosarcoma cell migration and invasion ability via targeting SOX7.
Bao Y; Chen B; Wu Q; Hu K; Xi X; Zhu W; Zhong X; Chen J
Clin Exp Med; 2017 Feb; 17(1):51-58. PubMed ID: 26515813
[TBL] [Abstract][Full Text] [Related]
12. Proteomics of osteosarcoma.
Bernardini G; Laschi M; Geminiani M; Santucci A
Expert Rev Proteomics; 2014 Jun; 11(3):331-43. PubMed ID: 24654989
[TBL] [Abstract][Full Text] [Related]
13. From genomics to metabolomics: emerging metastatic biomarkers in osteosarcoma.
Dean DC; Shen S; Hornicek FJ; Duan Z
Cancer Metastasis Rev; 2018 Dec; 37(4):719-731. PubMed ID: 30167827
[TBL] [Abstract][Full Text] [Related]
14. SLC34A2 Regulates the Proliferation, Migration, and Invasion of Human Osteosarcoma Cells Through PTEN/PI3K/AKT Signaling.
Liu X; Zhou X; Xu H; He Z; Shi X; Wu S
DNA Cell Biol; 2017 Sep; 36(9):775-780. PubMed ID: 28777670
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical Validation of Spontaneously Arising Canine Osteosarcoma as a Model for Human Osteosarcoma.
Al-Khan AA; Gunn HJ; Day MJ; Tayebi M; Ryan SD; Kuntz CA; Saad ES; Richardson SJ; Danks JA
J Comp Pathol; 2017 Nov; 157(4):256-265. PubMed ID: 29169619
[TBL] [Abstract][Full Text] [Related]
16. A humanized bone microenvironment uncovers HIF2 alpha as a latent marker for osteosarcoma.
Wagner F; Holzapfel BM; Martine LC; McGovern J; Lahr CA; Boxberg M; Prodinger PM; Grässel S; Loessner D; Hutmacher DW
Acta Biomater; 2019 Apr; 89():372-381. PubMed ID: 30836200
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin: its potential role in cancer of children and young adults.
Karpinsky G; Fatyga A; Krawczyk MA; Chamera M; Sande N; Szmyd D; Izycka-Swieszewska E; Bien E
Biomark Med; 2017 Apr; 11(4):389-402. PubMed ID: 28326824
[TBL] [Abstract][Full Text] [Related]
18. Osteopontin upregulates the expression of glucose transporters in osteosarcoma cells.
Hsieh IS; Yang RS; Fu WM
PLoS One; 2014; 9(10):e109550. PubMed ID: 25310823
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection.
Yan CH; Lv M; Li H; Song X; Yan F; Cao S; Ren X
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1371-8. PubMed ID: 25555465
[TBL] [Abstract][Full Text] [Related]
20. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma.
Zhao S; Kurenbekova L; Gao Y; Roos A; Creighton CJ; Rao P; Hicks J; Man TK; Lau C; Brown AM; Jones SN; Lazar AJ; Ingram D; Lev D; Donehower LA; Yustein JT
Oncogene; 2015 Sep; 34(39):5069-79. PubMed ID: 25579177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
